Program Status: Inactive / Discontinued

Reason: Registry status: TERMINATED

Stage at discontinuation: approved

Category Resource

Explore licensed vaccines, adverse event reporting data, and history for this disease.

View COVID-19 Vaccine Guide →

Development discontinued.

Development Phase Discontinued / Inactive Primary Status

Platform Technology Viral vector Biologic Architecture

Target Indication COVID-19 Pathogen / Antigen

Last Verified 2026-10-30 Tier 1 Multi-Source Checked

Multi-Jurisdiction Regulatory Status

Official licensing, rolling submissions, or authorization status tracked across major health authorities.

Regulatory Authority	Status & Details
US FDA	Not Filed / Pre-submission
EMA (Europe)	Not Filed / Pre-submission
Health Canada	Not Filed / Pre-submission
TGA (Australia)	Not Filed / Pre-submission

Progress and adoption outlook

Where this candidate sits on a fixed development ladder, and when a licence and a routine-use recommendation could follow in each jurisdiction, as scenario bands. Input grade: Discontinued or withdrawn; tracked, not projected.

90% of the laddernot projected

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
Submitted to a regulator
Under regulatory review
Approved / authorised
Recommended for routine use

Stopped at Approved / authorised

Discontinued. No adoption window is projected for a stopped programme.

Scientific Profile & Documentation

Platform Architecture: Viral vector
Lead Developer: Centre Hospitalier Universitaire de Saint Etienne
Next Expected Milestone: Primary completion (most advanced trial): 2022-02-14 (registry estimate)
Analyst & Development Notes: Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.
Primary Source Documentation: ClinicalTrials.gov NCT05037266 →

Registered Clinical Trials & Studies

Direct registry links to active, completed, or pivotal registration studies across phases.

NCT05037266 Discontinued / Inactive

Cohort Assessing the Immunogenicity and the Safety of the COVID-19 Vaccine Janssen in Healthy Volunteers Based on 2 Age

Status: Active / Ongoing • Expected Readout: 2022-02-14

Milestone Overview

Stage Verification

Discontinued / Inactive confirmed as of 2026-10-30.
Target Milestone

Primary completion (most advanced trial): 2022-02-14 (registry estimate)

Vaccine Data Navigator Candidate Profile Registry:

This candidate profile is indexed across all clinical development levels (Preclinical through Phase 1–3, Regulatory Filing, and Licensure) from primary registry databases (ClinicalTrials.gov, WHO ICTRP, FDA CBER, EMA, Health Canada, TGA Australia). Data are updated continuously to track global biologic and vaccine pipelines.